- Active Surveillance/Watchful Waiting (AS/WW) increased 4-fold in younger patients with low-risk prostate cancer and 3-fold in older patients during 2010-2015.
- Overall, AS/WW use in younger patients is less vs in older patients.
Why this matters
- QoL preservation by avoiding or delaying definitive treatment in low-risk patients appears to be a predominant driver in treatment decisions.
- Retrospective study of 50,302 patients with low-risk prostate cancer from Surveillance, Epidemiology, and End Results database during 2010-2015.
- Funding: None disclosed.
- 9973 patients (19.8%) were aged ≤55 years.
- Median follow-up was 41 months.
- AS/WW significantly increased during the study period:
- 4-fold increase in patients aged ≤55 years (8.61% to 34.56%; Ptrend<.001>
- 3-fold increase in patients aged ≥56 years (15.99% to 43.81%; Ptrend<.001>
- Lack of QoL measures and comorbidity data.